他汀类药物降低静脉血栓栓塞患者静脉事件的多中心随机对照预试验可行性研究
该预试验评估了瑞舒伐他汀辅助抗凝用于静脉血栓栓塞二级预防的招募可行性。六中心共筛选3391例,312例随机分配至瑞舒伐他汀20mg每日一次组或对照组。随访期间复发VTE事件瑞舒伐他汀组3例(1.9%)、对照组2例(1.3%),P=0.68。结论支持开展更大规模随机对照试验。
要点
- 瑞舒伐他汀20mg每日一次辅助抗凝用于VTE二级预防的招募可行。
- 月均随机化8.2±4.3例患者。
- 复发VTE事件两组差异无统计学意义(P=0.68)。
核心结论
- 该预试验支持开展更大规模随机对照试验以确定瑞舒伐他汀辅助用于VTE二级预防的疗效。
研究设计与样本
- 多中心随机对照预试验,纳入新诊断症状性近端深静脉血栓和/或肺栓塞且接受标准抗凝治疗的患者。
- 患者随机分配至瑞舒伐他汀20mg每日一次辅助治疗180天组或不使用瑞舒伐他汀组,随访6个月。
主要发现
- 3391例中1347例(39.7%)符合条件并接触,312例(23.1%)被随机化。
- 平均随机化率为每月8.2±4.3例患者。
- 随访期间共观察5例复发VTE事件:瑞舒伐他汀组3例(1.9%,2例肺栓塞、1例深静脉血栓),对照组2例(1.3%,2例肺栓塞),P=0.68。
- 瑞舒伐他汀组发生1例主要动脉事件,对照组0例(0.6% vs 0%,P=0.50)。
临床怎么用
- 该预试验结果为开展更大规模随机对照试验提供了可行性依据,尚不能据此改变临床实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Statins may reduce the risk for recurrent venous thromboembolism (VTE); however, no randomized trials have explored this hypothesis. We performed a pilot randomized trial to determine feasibility of recruitment for a larger trial of secondary VTE prevention with rosuvastatin. METHODS: Patients with a newly diagnosed symptomatic proximal deep vein thrombosis and/or pulmonary embolism, receiving standard anticoagulation, were randomly allocated to adjuvant rosuvastatin 20 mg once daily for 180 days or no rosuvastatin for 6 months. RESULTS: Between November 2016 and December 2019, 3391 patients were assessed for eligibility in six centers. Of these patients, 1347 (39.7%) were eligible and approached for participation in the trial and 312 (23.1%) were randomized. The mean rate of randomization was 8.2 ± 4.3 patients per month. During follow-up, five recurrent VTE events were observed, three (1.9%) in the rosuvastatin group (two pulmonary embolism, one deep vein thrombosis), and two (1.3%) in the control group (two pulmonary embolism; P = 0.68). One major arterial event occurred in the rosuvastatin arm and none in the control arm (0.6% vs. 0%, P = 0.50). CONCLUSION: This pilot trial supports the feasibility of a larger scale randomized controlled trial to determine the efficacy of adjuvant rosuvastatin for the secondary prevention of VTE.
引用
- Delluc A, Ghanima W, Kovacs MJ, et al. Statins for venous event reduction in patients with venous thromboembolism: A multicenter randomized controlled pilot trial assessing feasibility. J Thromb Haemost. 2021. PMID: 34564938. doi:10.1111/jth.15537
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。